Lilly Pulls COVID-19 Antibody Treatment From EU Review

Concern Over Resistance Of Delta Variant May Have Played A Part

 
• By Andrew McConaghie

While Lilly's antibody combination of etesevimab and bamlanivimab is still going strong in the US, the company has lost out to Roche's Ronapreve in the EU.

Viruses of different shapes, computer simulation
There is still an urgent need for therapies against COVID-19 • Source: Alamy

More from Europe

More from Geography